BioAge (BIOA) to Analyze Over 17,000 Biobank Samples for Drug Discovery

BioAge Labs, Inc. (NASDAQ:BIOA) is one of the 11 Best New Penny Stocks to Buy Right Now. On June 17, BioAge Labs, Inc. (NASDAQ:BIOA) announced a new initiative to profile and analyze samples from the HUNT Biobank in Norway.

The company will generate and analyze molecular profiles from more than 17,000 samples collected over decades of aging from more than 6,000 participants. BioAge Labs, Inc. (NASDAQ:BIOA) will use these samples to generate millions of molecular readouts.

Why Corcept Therapeutics Incorporated (CORT) Crashed On Monday

A biologist in a lab coat studying a culture of cells to find a cure for metabolic disorders.

By carefully analyzing this data along with the health records of the participants, BioAge Labs, Inc. (NASDAQ:BIOA) aims to expand the proprietary human aging data that supports the company’s drug-discovery platform. The company has exclusive rights to use this data for drug discovery.

This initiative builds on the company’s existing network of biobank partnerships. BioAge Labs, Inc. (NASDAQ:BIOA) expects this partnership to help accelerate its ability to find drug targets that maintain physiological resilience and help counter age-related disease.

BioAge Labs, Inc. (NASDAQ:BIOA) is a clinical-stage biopharmaceutical company focused on developing therapies to treat metabolic diseases by targeting the biology of human aging.

While we acknowledge the potential of BIOA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BIOA and that has a 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 10 Best American Semiconductor Stocks to Buy Now and 11 Best Fintech Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.